Back to top
more

Revolution Medicines (RVMD)

(Real Time Quote from BATS)

$36.92 USD

36.92
429,544

+0.29 (0.79%)

Updated Aug 4, 2025 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 45.4% upside potential for Revolution Medicines, Inc. (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 31.9% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Select Medical (SEM) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of 27.59% and 2.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.23% and 15.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q3 Earnings Expected to Decline

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.09% and -19.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q2 Earnings Expected to Decline

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -1.92% and 0.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session

by Zacks Equity Research

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2%

by Zacks Equity Research

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.